Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rubin

Showing results (681-690 of 791) with videos related to

Pageof 80
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Annals of Internal Medicine|December 1, 1993
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthmaE Israel, P Rubin, J P Kemp, et al.
Public Health Genomics|January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancerN T Brewer, J T Defrank, W K Chiu, et al.
British Journal of Cancer|May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsRobert B West, Brian P Rubin, Melinda A Miller, et al.
Oncogene|November 11, 2009
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profilingA H Beck, C-H Lee, D M Witten, et al.
Histopathology|February 13, 2013
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutationsDaniel Wetterskog, Paul M Wilkerson, Daniel N Rodrigues, et al.
Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.
The Journal of Pathology|November 24, 2015
Uterine adenosarcomas are mesenchymal neoplasmsSalvatore Piscuoglio, Kathleen A Burke, Charlotte K Y Ng, et al.
Pageof 80

Showing results (681-690 of 791) with videos related to

Sort By:
Pageof 80
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Annals of Internal Medicine|December 1, 1993
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthmaE Israel, P Rubin, J P Kemp, et al.
Public Health Genomics|January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancerN T Brewer, J T Defrank, W K Chiu, et al.
British Journal of Cancer|May 25, 2019
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsRobert B West, Brian P Rubin, Melinda A Miller, et al.
Oncogene|November 11, 2009
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profilingA H Beck, C-H Lee, D M Witten, et al.
Histopathology|February 13, 2013
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutationsDaniel Wetterskog, Paul M Wilkerson, Daniel N Rodrigues, et al.
Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.
The Journal of Pathology|November 24, 2015
Uterine adenosarcomas are mesenchymal neoplasmsSalvatore Piscuoglio, Kathleen A Burke, Charlotte K Y Ng, et al.
Pageof 80